Daihan Pharmaceutical Co.Ltd (023910) — Cash Flow Reinvestment Rate
Daihan Pharmaceutical Co.Ltd (023910) has a Cash Flow Reinvestment Rate of 1.44x as of September 2025, reinvesting ₩13.63 Billion (capex ₩10.79 Billion plus investments ₩-2.84 Billion) from operating cash flow of ₩9.47 Billion. See cash generation quality of Daihan Pharmaceutical Co.Ltd to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Daihan Pharmaceutical Co.Ltd Cash Flow Reinvestment Rate (2014–2024)
Historical reinvestment intensity for Daihan Pharmaceutical Co.Ltd across 11 annual periods. For the full cash flow conversion analysis, see 023910 cash flow metrics.
Annual Cash Flow Reinvestment Rate for Daihan Pharmaceutical Co.Ltd (2014–2024)
Year-by-year capital reinvestment analysis for Daihan Pharmaceutical Co.Ltd. See 023910 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 2.48x | ₩88.43 Billion | ₩35.64 Billion | ₩15.80 Billion | ▲ +145.5% |
| 2023 | 1.01x | ₩39.28 Billion | ₩38.86 Billion | ₩21.28 Billion | ▲ +232.5% |
| 2022 | 0.30x | ₩8.81 Billion | ₩29.00 Billion | ₩8.62 Billion | ▲ +1.7% |
| 2021 | 0.30x | ₩12.13 Billion | ₩40.62 Billion | ₩11.85 Billion | ▼ -8.3% |
| 2020 | 0.33x | ₩10.96 Billion | ₩33.63 Billion | ₩5.36 Billion | ▼ -53.7% |
| 2019 | 0.70x | ₩24.84 Billion | ₩35.26 Billion | ₩17.30 Billion | ▼ -33.8% |
| 2018 | 1.06x | ₩47.80 Billion | ₩44.94 Billion | ₩46.69 Billion | ▲ +2.3% |
| 2017 | 1.04x | ₩21.26 Billion | ₩20.45 Billion | ₩21.05 Billion | ▲ +18.5% |
| 2016 | 0.88x | ₩24.50 Billion | ₩27.92 Billion | ₩21.90 Billion | ▲ +290.5% |
| 2015 | 0.22x | ₩4.04 Billion | ₩17.98 Billion | ₩3.96 Billion | ▼ -82.1% |
| 2014 | 1.26x | ₩11.90 Billion | ₩9.48 Billion | ₩10.47 Billion | — |